News articles about Odonate Therapeutics (NASDAQ:ODT) have been trending somewhat negative this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Odonate Therapeutics earned a news sentiment score of -0.06 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.2851001096691 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Zacks: Brokerages Set $40.00 Target Price for Odonate Therapeutics Inc (ODT) (americanbankingnews.com)
- Zacks Investment Research Downgrades Odonate Therapeutics (ODT) to Sell (americanbankingnews.com)
- Odonate Therapeutics Inc (ODT) Given $40.00 Consensus Price Target by Brokerages (americanbankingnews.com)
- Analysts Anticipate Odonate Therapeutics Inc (ODT) to Post -$0.86 EPS (americanbankingnews.com)
Several research analysts have commented on ODT shares. Cowen started coverage on Odonate Therapeutics in a research report on Tuesday, January 2nd. They set an “outperform” rating on the stock. Jefferies Group started coverage on Odonate Therapeutics in a research report on Tuesday, January 2nd. They set a “buy” rating and a $40.00 price target on the stock. Zacks Investment Research lowered Odonate Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, Goldman Sachs Group started coverage on Odonate Therapeutics in a research report on Tuesday, January 2nd. They set a “neutral” rating and a $27.00 price target on the stock.
Odonate Therapeutics (NASDAQ:ODT) last released its quarterly earnings results on Wednesday, February 14th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.14). equities analysts predict that Odonate Therapeutics will post -4.3 EPS for the current year.
In related news, CEO Kevin C. Tang bought 28,612 shares of the company’s stock in a transaction dated Tuesday, February 27th. The shares were acquired at an average price of $27.42 per share, with a total value of $784,541.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Kevin C. Tang bought 39,083 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was bought at an average cost of $27.17 per share, for a total transaction of $1,061,885.11. The disclosure for this purchase can be found here. In the last three months, insiders bought 210,000 shares of company stock worth $5,113,567.
ILLEGAL ACTIVITY NOTICE: “Odonate Therapeutics (ODT) Receives Coverage Optimism Rating of -0.06” was first reported by BBNS and is the property of of BBNS. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/13/odonate-therapeutics-odt-receives-coverage-optimism-rating-of-0-06/2022769.html.
Odonate Therapeutics Company Profile
Odonate Therapeutics, Inc, formerly Odonate Therapeutics, LLC, is a pharmaceutical company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. It is focused on the development of tesetaxel, a novel chemotherapy agent. It has completed Phase-II studies in patients with metastatic breast cancer (MBC).
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.